Sort
82,697 grants matching “vaccine development”
A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENT
$856,761University Of Wisconsin Madison · R01 · FY2004 · AI
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities
$856,702Charles T Roberts · Oregon Health & Science University · R01 · FY2019 · DK
Collaborative IVR Platform for Multilingual Patient Outreach and Education
$856,683William Z Tan · Transcendent International, Llc · R44 · FY2010 · DK
Kinetics, evolution, and effector function of Fc repertoires during vaccination with native-like Env trimers
$856,679D. Noah Sather · Seattle Children'S Hospital · R01 · FY2023 · AI
Engineering sustainable squalene analogues for novel vaccine adjuvant emulsions
$856,636Christopher B Fox · Access To Advanced Health Institute · R01 · FY2019 · AI
ADOLESCENT MEDICINE TRIALS UNIT
$856,517Donna Futterman · Albert Einstein College Of Medicine · U01 · FY2011 · HD
Disease Modeling of Influenza and Other Emerging Respiratory Viral Pathogens
$856,485Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodies
$856,430James J Kobie · University Of Alabama At Birmingham · R01 · FY2021 · AI
REPTOR: accelerating antibody discovery and improving hits with machine learning
$856,396Natalie Castellana · Abterra Biosciences, Inc. · R44 · FY2024 · GM
Novel Targets for Vaccine Therapy
$856,385Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2016 · CA
Collaborative Research: Ideas Lab: The Role of Extracellular RNA in Intercellular and Interkingdom Communication
$856,318Kendall R Corbin · University Of Kentucky Research Foundation · · FY2023 · BIO
CTL for supertype natural IgE cytotoxic peptide (nECP) to guard against allergic asthma
$856,276Swey-Shen Chen · Ige Therapeutics, Inc. · R44 · FY2017 · AI
Entry and replication of positive-sense, RNA viruses
$856,275Joseph Marcotrigiano · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Mechanisms of Antibody Fc Mediated Protection
$856,265Georgia D Tomaras · Duke University · P01 · FY2023 · AI
Pediatric Respiratory Illness Measurement System (PRIMES) Implementation in Community Hospital Settings
$856,262Rita Mangione-Smith · Kaiser Foundation Research Institute · R01 · FY2021 · HL
Efficacy of Strain 68-1 RhCMV Vectors Expressing 5' Leader Polypeptides
$856,238Scott G Hansen · Oregon Health & Science University · R01 · FY2017 · AI
Project 1: Immunization strategies to elicit broadly neutralizing antibodies against HIV-1
$856,199Pamela J Bjorkman · California Institute Of Technology · P01 · FY2020 · AI
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent
$856,160Radhakrishnan P Iyer · Spring Bank Technologies, Inc. · R01 · FY2014 · AI
DEVELOPMENT OF A LIPOSOMAL PNEUMOCOCCAL VACCINE FOR CLINICAL READINESS
$856,101Charles Houston Jones · Abcombi Biosciences, Inc. · R44 · FY2022 · AI
Genome-Wide Association Study of HIV-1 Host Genetics Among Injection Drug Users
$856,000David L Valle · Johns Hopkins University · N01 · FY2011 · DA
Development and In Vivo Characterization of Safety-Enhanced RhCMV/SIV Vectors
$855,999Louis J. Picker · Oregon Health & Science University · R01 · FY2011 · AI
Humoral Correlates of Protection Against HIV
$855,955Ruth Margrit Ruprecht · Dana-Farber Cancer Inst · R01 · FY2012 · AI
Harnessing oral mucosa vaccination to drive protective HIV antibody responses
$855,888Donald L Sodora · Seattle Biomedical Research Institute · R01 · FY2017 · DE
Revolutionary Eilat-based Chikungunya Vaccine Vector
$855,817Tian Wang · University Of Texas Med Br Galveston · R01 · FY2017 · AI
Pathogenesis of HIV and HCV in Hemophilia: HGDS
$855,816Children'S Hospital Los Angeles · R01 · FY2001 · HD